TMCnet News
Research and Markets: The Global Breast Cancer Imaging Market to Grow From a Value of $972m in 2011 to $1.7 Billion by 2018 Says Latest ReportDUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/f37fpn/medipoint_breast) has announced the addition of the "MediPoint: Breast Cancer Imaging - Global Analysis and Market Forecasts" report to their offering. Digital Breast Tomosynthesis to Revive Matured Breast Cancer Imaging Markets Digital breast tomosynthesis (DBT) is due to revive the breast cancer imaging market in the developed world, installations expected to increase four fold in the US by 2016, and double in the EU, according to new analysis. The new report states that the US is the biggest contributor in the global breast cancer imaging market, and US revenues dipped for new installations of full-field digital mammography equipment after 2009, when the US market began to show signs of saturation. However, the positive reception of DBT by the radiology community may help the market out of this slump. The authors predicts that DBT's share in new breast imaging system installations in the US alone will grow from 10% in 2011 to a 75% share in 2018, lading the global breast cancer imaging market to grow from a value of $972m in 2011 to $1.7 billion by 2018. Trials will play a significant role in the fate of the DBT market. The ongoing Oslo Breast Cancer Screening Trial is estimated to enroll 25,000 women to evaluate the effectiveness of DBT. Interim results released earlier this year were promising, showing that using DBT in combination with conventional 2D mammography improved the detection rate of all cancers by 27%, a 40% increase in the detection of invasive cancers, and reduced false-positive rates by 15% when compared to 2D mammography alone. Hologic stated that it observed a significant increase in interest levels for DBT after the release of this initial data, and full trial results in 2015 are expected to further validate the push towards DBT as the paradigm in breast cancer detection in the future, quantifying the benefits offered over current screening methods. The UK's National Institute for Health Research (NIHR) is also currently conducting a DBT trial, TOMMY, due to be completed in 2015 and is expected to set the benchmark for the future national uptake of DBT. The authors predicts that new installations for DBT are likely to double in the UK by 2016, and the conclusions of TOMMY in 2015 will lend credence to this forecast. Companies Mentioned:
For more information visit http://www.researchandmarkets.com/research/f37fpn/medipoint_breast About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
|
